Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea

ConclusionsThese data indicate the good tolerability and potential efficacy of darinaparsin in patients with relapsed/refractory peripheral T-cell lymphoma. Darinaparsin 300  mg/m2/day for 5 consecutive days in 3-week  cycles is the recommended regimen for phase II study.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research